Insider Buying Boosts Healthcare Stocks: Eli Lilly, Teleflex, and Calcimedica

Healthcare stocks Eli Lilly, Teleflex, and Calcimedica are experiencing insider buying activity, particularly in Q3 2025. Eli Lilly faces competition for GLP-1 sales but has a high degree of insider confidence, with established business, pipeline of new treatments, and balance sheet health. Teleflex is on track to sustain growth and amplify its outlook with a recent acquisition, while Calcimedica has seen insider buying and a recent stock price surge. Insiders' purchases suggest potential value and growth for these stocks.

Healthcare stocks Eli Lilly (NYSE: LLY), Teleflex (NYSE: TFX), and Calcimedica (NASDAQ: CALC) have seen notable insider buying activity in Q3 2025, suggesting potential value and growth opportunities for investors.

Eli Lilly

Eli Lilly faces competition for its GLP-1 sales, which has led to a decline in share price. However, insiders, including the CEO, EVP, and directors, have been buying the stock, indicating high confidence in its value. Despite the competition, Eli Lilly maintains a 57% GLP-1 market share through value-based pricing and accessibility programs. The company's strong revenue growth and expanded pipeline in hypertension and osteoarthritis reinforce long-term growth prospects [3]. The insider buying, combined with an established blue-chip business and a healthy balance sheet, makes Eli Lilly an attractive buy for investors [1].

Teleflex

Teleflex has been experiencing industry headwinds, including post-COVID normalization and divestitures. However, the company is on track to sustain growth and has amplified its outlook with a recent acquisition. Insiders, including four directors and the CEO, have been buying the stock, marking the first buying activity in years. Institutions, which own about 95% of the company, have also reverted to buying in the first half of Q3, providing a potential tailwind for price action in future quarters. The upcoming Q3 report could serve as a catalyst for a rebound, as the company raised its guidance for the quarter above the consensus [1].

Calcimedica

Calcimedica has seen insider buying, including numerous purchases by the CEO, directors, and other executives, which collectively own more than 40% of the stock. The company's price action in 2025 is influenced by positive trial results. However, there are risks, particularly from institutions, which own nearly all of the remaining shares and are selling on balance in Q3. The company forecasts running out of capital by the middle of 2026, which could result in dilutive actions. Despite these risks, the insider buying suggests potential value and growth for Calcimedica [1].

In conclusion, insider buying activity in Q3 2025 indicates potential value and growth opportunities in Eli Lilly, Teleflex, and Calcimedica. However, investors should carefully consider the risks and market dynamics associated with each company.

References

[1] https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/34282844/buy-sell-or-hold-insiders-pile-into-these-3-healthcare-stocks/
[2] https://www.nasdaq.com/articles/buy-sell-or-hold-insiders-pile-these-3-healthcare-stocks
[3] https://www.ainvest.com/news/eli-lilly-pricing-strategy-pipeline-resilience-glp-1-obesity-market-strategic-buying-opportunity-2508/